Additionally, subcutaneous desmopressin testing should be considered for patients unresponsive to intranasal desmopressin. All 14 patients who underwent subcutaneous desmopressin challenge testing met criteria for response while sustained response was observed in all 12 patients. This retrospective cohort study reviewed all patients with VWD (type 1, 2 M) or associated diseases (qualitative platelet disorders) who underwent desmopressin challenge tests via intranasal and/or subcutaneous routes. All seven patients met criteria for response to subcutaneous desmopressin, including three patients who did not respond to intranasal (ID 1,2,6). [Extracted from the article]